Myelofibrosis breakthrough? Incyte’s INCA033989 delivers clinical and molecular wins

How INCA033989 is redefining treatment targets for CALR-mutant myeloproliferative neoplasms

Incyte Corporation (Nasdaq: INCY) has released new Phase 1 clinical trial data showing promising early efficacy and safety for its novel monoclonal antibody INCA033989, a first-in-class agent targeting mutant calreticulin (mutCALR) in patients with myelofibrosis and essential thrombocythemia. The preliminary results, unveiled at the 2025 American Society of Hematology Annual Meeting in Orlando, suggest that the investigational therapy may represent a meaningful step forward for patients with CALR-mutated myeloproliferative neoplasms, particularly those who have limited options after JAK inhibitor treatment.

The trials evaluated INCA033989 both as monotherapy and in combination with Incyte’s approved JAK1/JAK2 inhibitor Jakafi (ruxolitinib). In both settings, the antibody achieved reductions in spleen volume, improvement in anemia, and symptom relief. Importantly, molecular and histological data indicated early signals of disease modification, including reductions in mutCALR variant allele frequency and improvements in bone marrow architecture.

Incyte confirmed it plans to initiate registrational programs for both myelofibrosis and essential thrombocythemia indications in 2026, positioning INCA033989 as a pipeline cornerstone beyond Jakafi.

Why is mutCALR emerging as a high-value target in hematologic malignancies?

Mutations in the CALR gene represent a pathogenic driver in up to one-third of patients with myeloproliferative neoplasms. These somatic mutations result in abnormal protein signaling that supports malignant stem cell proliferation and disrupts normal hematopoiesis. Unlike JAK2 or MPL mutations, which have seen targeted development efforts for over a decade, mutCALR has historically remained undrugged due to its intracellular location and complex biology.

The therapeutic rationale behind INCA033989 centers on its selective binding to mutant calreticulin proteins, which are aberrantly expressed on the surface of malignant hematopoietic cells. This unique characteristic makes mutCALR an ideal neoantigen, enabling monoclonal antibody targeting without affecting healthy cells. By selectively eliminating mutCALR-expressing clones, INCA033989 has the potential to restore normal hematopoiesis while sparing non-mutant cells.

What efficacy signals were observed in the INCA033989 monotherapy arm?

Incyte evaluated INCA033989 as a monotherapy in a population of myelofibrosis patients with CALR mutations who were either resistant, intolerant, or ineligible for prior JAK inhibitor therapy. Dosing ranged from 24 mg to 2,500 mg. Among 36 evaluable patients, 41.7 percent achieved at least a 25 percent reduction in spleen volume at Week 24, while 33.3 percent met the more stringent 35 percent reduction threshold. Notably, responses were higher in JAK inhibitor-naive patients, with 71.4 percent reaching SVR25 and 57.1 percent achieving SVR35.

Anemia improvement was also substantial. Among 25 evaluable anemic patients, 56 percent experienced a clinical anemia response and 40 percent had a major response, suggesting potential impact on erythropoiesis. Nearly all treated patients reported symptomatic relief, with 60 percent achieving at least a 50 percent reduction in total symptom score. This was observed even among heavily pre-treated patients with significant disease burden.

Reductions in the mutCALR variant allele frequency were observed in 89.4 percent of patients who had at least one post-baseline measurement. A subset of 10.6 percent achieved a reduction of 25 percent or more, supporting the hypothesis that the antibody may be eliminating pathogenic clones at the molecular level.

What did the combination therapy with ruxolitinib reveal about synergistic potential?

In a separate trial arm, INCA033989 was administered alongside ruxolitinib in patients who had experienced a suboptimal response to JAK inhibitor monotherapy. The combination therapy was well tolerated and yielded encouraging preliminary signals of efficacy.

At Week 24, half of the 12 evaluable patients achieved a 25 percent reduction in spleen volume, and 25 percent reached the 35 percent threshold. Symptom improvement was seen in over 80 percent of treated patients, and 33 percent reached the total symptom score reduction benchmark of 50 percent by Week 24. Among patients with anemia, most remained stable, and one patient showed a major anemia response despite not being transfusion dependent.

This data suggests a possible additive benefit from combining JAK-STAT pathway inhibition with targeted eradication of mutCALR-expressing clones, which could form the basis for future standard-of-care combinations.

How do bone marrow findings support the potential for disease modification?

In addition to clinical and molecular response, Incyte presented exploratory histologic data that further substantiated the disease-modifying potential of INCA033989. Bone marrow samples revealed reductions in mutant CALR-positive hematopoietic stem and progenitor cells, as well as megakaryocytes, the cells responsible for platelet production. These reductions were paired with increases in wild-type megakaryocytes, indicating a potential shift toward normal bone marrow function.

In anemic patients, the presence of CD71-positive erythroid progenitor cells increased, aligning with observed hemoglobin gains and reinforcing the therapy’s potential impact on erythropoiesis. Such histologic remodeling is rarely seen with conventional JAK inhibitors and, if validated in larger studies, may support a differentiated mechanism of action for INCA033989.

What does the safety profile of INCA033989 indicate about long-term tolerability?

INCA033989 demonstrated a favorable safety profile in both monotherapy and combination arms. No dose-limiting toxicities were reported, and the maximum tolerated dose was not reached. The majority of adverse events were mild to moderate and manageable.

In the monotherapy group, adverse events included anemia, fatigue, thrombocytopenia, arthralgia, and transient liver enzyme elevations. Sixteen patients experienced Grade 3 or higher events, with neutropenia being the most frequent. Only two patients discontinued due to treatment-emergent adverse events. In the combination cohort, side effects were similar in nature and severity, with anemia and thrombocytopenia as the most common Grade 3 or higher events. Again, only two patients discontinued treatment for tolerability reasons.

Analysts observing the hematology space noted that the low discontinuation rates and broad safety window make INCA033989 a strong candidate for chronic use, particularly in a disease setting where long-term management is often necessary.

What is the regulatory and strategic outlook for Incyte’s mutCALR program?

Incyte’s broader clinical strategy around INCA033989 includes a Phase 1 program enrolling up to 455 patients with either myelofibrosis or essential thrombocythemia across two studies (NCT05936359 and NCT06034002). Based on current data, the United States Food and Drug Administration has already granted Breakthrough Therapy designation for INCA033989 in essential thrombocythemia patients with Type 1 CALR mutations who are resistant or intolerant to cytoreductive therapy.

A registrational trial in myelofibrosis is scheduled to begin in 2026. Analysts believe that inclusion of molecular and histological endpoints may enhance regulatory appeal and pave the way for label expansion if confirmed in later-phase studies. Incyte is also expected to pursue development in patients with non-Type 1 CALR mutations, which could broaden the addressable patient population significantly.

How are investors and analysts interpreting the ASH 2025 data release?

Shares of Incyte Corporation have seen mild positive movement following the ASH presentations, with buy-side investors highlighting the durability of the response signals and the differentiated mechanism of action. Institutional sentiment appears cautiously optimistic as stakeholders wait for expanded data in larger cohorts and potential progression into registrational trials.

The company’s post-Jakafi growth trajectory remains a central focus for analysts, particularly as biosimilar competition and class-wide JAK safety concerns shift attention toward novel targets. INCA033989 is being positioned as a potential cornerstone of Incyte’s next wave of hematology innovation, with analysts pointing to disease-modifying potential as a key differentiator in a crowded and maturing market.

What are the key takeaways from Incyte’s ASH 2025 INCA033989 data in myelofibrosis?

• INCA033989 demonstrated robust clinical responses in spleen volume reduction, symptom score, and anemia.

• A majority of patients achieved reductions in mutCALR allele burden, supporting a molecular response.

• Bone marrow analyses showed restoration of normal progenitor cell populations, suggesting disease-modifying activity.

• The antibody showed a consistent safety profile, with low discontinuation and no dose-limiting toxicity.

• Combination therapy with ruxolitinib was well-tolerated and showed additive benefit.

• Breakthrough Therapy designation has been granted for ET, and registrational trials in MF and ET are planned for 2026.

• Investor sentiment is positive, with the mutCALR program seen as a pipeline-defining asset for Incyte.